SCHEMBL2903666

SCHEMBL2903666

COc1cc(C=C(C(=O)OC(C)C)C(=O)OC(C)C)cc(OC)c1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTP4A3 O75365 1/20 0.57
PTP4A2 Q12974 1/20 0.57
PTP4A1 Q93096 1/20 0.57
CYP3A4 P08684 3/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2B6 P20813 2/20 0.49
CYP2D6 P10635 1/20 0.49
PKM P14618 2/20 0.47
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47
MAPT P10636 6/20 0.45
KMT2A Q03164 6/20 0.45
GAA P10253 2/20 0.45
TDP1 Q9NUW8 2/20 0.43
ABL1 P00519 2/20 0.42
BCR P11274 1/20 0.42
LMNA P02545 3/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23530158 0.93 PTP4A3 (0.54) PTP4A3PTP4A2PTP4A1CYP3A4CYP1A2
SCHEMBL2269598 0.93 PTP4A3 (0.54) PTP4A3PTP4A2PTP4A1CYP3A4CYP1A2
SCHEMBL8331758 0.88 HPGD (0.49) PTP4A3PTP4A2PTP4A1MAPTKMT2A
SCHEMBL29601206 0.84 MAPT (0.67) CYP3A4CYP1A2CYP2C9CYP2B6CYP2D6
SCHEMBL168150 0.84 MAPT (0.67) CYP3A4CYP1A2CYP2C9CYP2B6CYP2D6
SCHEMBL20162247 0.84 PTP4A3 (0.43) PTP4A3PTP4A2PTP4A1CYP3A4CYP1A2
SCHEMBL20395525 0.83 MAPT (0.58) CYP3A4CYP1A2CYP2C9CYP2B6CYP2D6
SCHEMBL20162246 0.81 PTP4A3 (0.41) PTP4A3PTP4A2PTP4A1CYP1A2CYP2C9
SCHEMBL11769950 0.81 PTP4A3 (0.45) PTP4A3PTP4A2PTP4A1MAPTKMT2A
SCHEMBL8842877 0.80 PTP4A3 (0.51) PTP4A3PTP4A2PTP4A1CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12453682-B2 Composition comprising at least 5% by weight of titanium oxides, an α-cyanodiphenylacrylate derivative and a 4-hydroxybenzylidenemalonate or 4-hydroxycinnamate derivative L'ORÉAL (FR) 2025-10-28 US claimed
US-20230044544-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN a-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE L'OREAL (FR) 2023-02-09 US claimed
EP-4076677-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN A-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE L'OREAL (FR) 2022-10-26 EP claimed
WO-2021122039-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN A-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE L'OREAL (FR) 2021-06-24 WO claimed
EP-1635777-B1 PHOTOSTABLE ORGANIC SUNSCREEN COMPOSITION MERCK PATENT GMBH (DE) 2012-06-06 EP claimed
EP-1747773-B1 Photostable organic sunscreen compositions with antioxidant properties MERCK PATENT GMBH (DE) 2010-08-04 EP claimed
EP-1406582-B1 PHOTOSTABLE ORGANIC SUNSCREEN COMPOUNDS WITH ANTIOXIDANT PROPERTIES AND COMPOSITIONS OBTAINED THEREFROM MERCK PATENT GMBH (DE) 2006-10-25 EP claimed
CN-1798538-A Photostable organic sunscreen composition MERCK PATENT GMBH (DE) 2006-07-05 CN claimed
US-12453682-B2 Composition comprising at least 5% by weight of titanium oxides, an α-cyanodiphenylacrylate derivative and a 4-hydroxybenzylidenemalonate or 4-hydroxycinnamate derivative L'ORÉAL (FR) 2025-10-28 US disclosed
US-20230044544-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN a-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE L'OREAL (FR) 2023-02-09 US disclosed
EP-4076677-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN A-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE L'OREAL (FR) 2022-10-26 EP disclosed
WO-2021122039-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN A-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE L'OREAL (FR) 2021-06-24 WO disclosed
US-20210161783-A1 USE OF SPECIFIC BENZYLIDENE MALONATES FOR PROTECTING THE SKIN FROM CHEMICALLY INDUCED STRESS MERCK PATENT GMBH (DE) 2021-06-03 US disclosed
US-20180207080-A1 COMPOSITIONS OF FLUORINATED SURFACTANTS AND ANTIOXIDANTS MERCK PATENT GMBH (DE) 2018-07-26 US disclosed
EP-3322400-A1 COMPOSITIONS OF FLUORINATED SURFACTANTS AND ANTIOXIDANTS Merck Patent GmbH (DE) 2018-05-23 EP disclosed
CN-1798538-A Photostable organic sunscreen composition MERCK PATENT GMBH (DE) 2006-07-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230044544-A1 COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN a-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVE HAAO, HAO2, HPD PTP4A3 1288/4885PTP4A2 1754/4885PTP4A1 1193/4885
US-12453682-B2 Composition comprising at least 5% by weight of titanium oxides, an α-cyanodiphenylacrylate derivative and a 4-hydroxybenzylidenemalonate or 4-hydroxycinnamate derivative HAAO, HPD, P4HA1 PTP4A3 1306/4885PTP4A2 1805/4885PTP4A1 1191/4885
US-20180207080-A1 COMPOSITIONS OF FLUORINATED SURFACTANTS AND ANTIOXIDANTS LPO, CAT, GPX4 PTP4A3 3582/4885PTP4A2 4139/4885PTP4A1 3983/4885
US-20210161783-A1 USE OF SPECIFIC BENZYLIDENE MALONATES FOR PROTECTING THE SKIN FROM CHEMICALLY INDUCED STRESS MAL2, GAA, ME2 PTP4A3 1356/4885PTP4A2 1439/4885PTP4A1 1509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.